These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30690309)

  • 1. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States.
    Zhou X; de Luise C; Gaffney M; Burt CW; Scott DA; Gatto N; Center KJ
    Int J Pediatr Otorhinolaryngol; 2019 Apr; 119():96-102. PubMed ID: 30690309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambulatory Visits for Otitis Media before and after the Introduction of Pneumococcal Conjugate Vaccination.
    Kawai K; Adil EA; Barrett D; Manganella J; Kenna MA
    J Pediatr; 2018 Oct; 201():122-127.e1. PubMed ID: 29958675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study.
    Pichichero M; Kaur R; Scott DA; Gruber WC; Trammel J; Almudevar A; Center KJ
    Lancet Child Adolesc Health; 2018 Aug; 2(8):561-568. PubMed ID: 30119715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media.
    Dagan R; Van Der Beek BA; Ben-Shimol S; Pilishvili T; Givon-Lavi N
    Clin Infect Dis; 2021 Aug; 73(4):650-658. PubMed ID: 33507250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.
    Grijalva CG; Poehling KA; Nuorti JP; Zhu Y; Martin SW; Edwards KM; Griffin MR
    Pediatrics; 2006 Sep; 118(3):865-73. PubMed ID: 16950975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Otitis Media Episodes and Pressure Equalization Tube Insertions Among Young Children Following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine: A Birth Cohort-based Study.
    Wiese AD; Huang X; Yu C; Mitchel EF; Kyaw MH; Griffin MR; Grijalva CG
    Clin Infect Dis; 2019 Nov; 69(12):2162-2169. PubMed ID: 30770533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom.
    Lau WC; Murray M; El-Turki A; Saxena S; Ladhani S; Long P; Sharland M; Wong IC; Hsia Y
    Vaccine; 2015 Sep; 33(39):5072-9. PubMed ID: 26297875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substantial reduction of antibiotic-non-susceptible pneumococcal otitis media following PCV7/PCV13 sequential introduction.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; van der Beek BA; Leibovitz E; Dagan R
    J Antimicrob Chemother; 2020 Oct; 75(10):3038-3045. PubMed ID: 32946586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2021 Feb; 17(2):517-526. PubMed ID: 32574101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of Streptococcus pneumoniae causing acute otitis media among children in Southern Catalonia throughout 2007-2013: Incidence, serotype distribution and vaccine's effectiveness.
    Ochoa-Gondar O; Figuerola-Massana E; Vila-Corcoles A; Aguirre CA; de Diego C; Satue E; Gomez F; Raga X;
    Int J Pediatr Otorhinolaryngol; 2015 Dec; 79(12):2104-8. PubMed ID: 26453272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2016 Sep; 63(5):611-8. PubMed ID: 27225239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
    Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
    Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.